 Drug Resistance, Neoplasm
"Drug Resistance, Neoplasm" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
| Descriptor ID |
D019008
|
| MeSH Number(s) |
G07.690.773.984.395
|
| Concept/Terms |
Drug Resistance, Neoplasm- Drug Resistance, Neoplasm
- Resistance, Antineoplastic Agent
- Resistance, Antineoplastic Drug
- Drug Resistance, Antineoplastic
- Neoplasm Drug Resistance
- Antineoplastic Agent Resistance
- Antineoplastic Drug Resistance
|
Below are MeSH descriptors whose meaning is more general than "Drug Resistance, Neoplasm".
Below are MeSH descriptors whose meaning is more specific than "Drug Resistance, Neoplasm".
This graph shows the total number of publications written about "Drug Resistance, Neoplasm" by people in this website by year, and whether "Drug Resistance, Neoplasm" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 2 | 2 | | 1998 | 0 | 3 | 3 | | 1999 | 0 | 3 | 3 | | 2000 | 1 | 3 | 4 | | 2001 | 0 | 3 | 3 | | 2002 | 0 | 2 | 2 | | 2003 | 0 | 5 | 5 | | 2004 | 1 | 1 | 2 | | 2005 | 3 | 6 | 9 | | 2006 | 0 | 3 | 3 | | 2007 | 5 | 11 | 16 | | 2008 | 4 | 4 | 8 | | 2009 | 7 | 6 | 13 | | 2010 | 10 | 14 | 24 | | 2011 | 6 | 11 | 17 | | 2012 | 6 | 15 | 21 | | 2013 | 15 | 17 | 32 | | 2014 | 12 | 10 | 22 | | 2015 | 11 | 13 | 24 | | 2016 | 13 | 28 | 41 | | 2017 | 10 | 21 | 31 | | 2018 | 10 | 24 | 34 | | 2019 | 14 | 9 | 23 | | 2020 | 6 | 6 | 12 | | 2021 | 2 | 4 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Drug Resistance, Neoplasm" by people in Profiles.
-
Brose MS, Robinson B, Sherman SI, Krajewska J, Lin CC, Vaisman F, Hoff AO, Hitre E, Bowles DW, Hernando J, Faoro L, Banerjee K, Oliver JW, Keam B, Capdevila J. Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2021 08; 22(8):1126-1138.
-
Awad MM, Liu S, Rybkin II, Arbour KC, Dilly J, Zhu VW, Johnson ML, Heist RS, Patil T, Riely GJ, Jacobson JO, Yang X, Persky NS, Root DE, Lowder KE, Feng H, Zhang SS, Haigis KM, Hung YP, Sholl LM, Wolpin BM, Wiese J, Christiansen J, Lee J, Schrock AB, Lim LP, Garg K, Li M, Engstrom LD, Waters L, Lawson JD, Olson P, Lito P, Ou SI, Christensen JG, Jänne PA, Aguirre AJ. Acquired Resistance to KRASG12C Inhibition in Cancer. N Engl J Med. 2021 06 24; 384(25):2382-2393.
-
Giddings EL, Champagne DP, Wu MH, Laffin JM, Thornton TM, Valenca-Pereira F, Culp-Hill R, Fortner KA, Romero N, East J, Cao P, Arias-Pulido H, Sidhu KS, Silverstrim B, Kam Y, Kelley S, Pereira M, Bates SE, Bunn JY, Fiering SN, Matthews DE, Robey RW, Stich D, D'Alessandro A, Rincon M. Mitochondrial ATP fuels ABC transporter-mediated drug efflux in cancer chemoresistance. Nat Commun. 2021 05 14; 12(1):2804.
-
Stratigos AJ, Sekulic A, Peris K, Bechter O, Prey S, Kaatz M, Lewis KD, Basset-Seguin N, Chang ALS, Dalle S, Orland AF, Licitra L, Robert C, Ulrich C, Hauschild A, Migden MR, Dummer R, Li S, Yoo SY, Mohan K, Coates E, Jankovic V, Fiaschi N, Okoye E, Bassukas ID, Loquai C, De Giorgi V, Eroglu Z, Gutzmer R, Ulrich J, Puig S, Seebach F, Thurston G, Weinreich DM, Yancopoulos GD, Lowy I, Bowler T, Fury MG. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. Lancet Oncol. 2021 06; 22(6):848-857.
-
Hicks HM, McKenna LR, Espinoza VL, Pozdeyev N, Pike LA, Sams SB, LaBarbera D, Reigan P, Raeburn CD, E Schweppe R. Inhibition of BRAF and ERK1/2 has synergistic effects on thyroid cancer growth in vitro and in vivo. Mol Carcinog. 2021 03; 60(3):201-212.
-
Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, Raje N, Lin Y, Siegel D, Oriol A, Moreau P, Yakoub-Agha I, Delforge M, Cavo M, Einsele H, Goldschmidt H, Weisel K, Rambaldi A, Reece D, Petrocca F, Massaro M, Connarn JN, Kaiser S, Patel P, Huang L, Campbell TB, Hege K, San-Miguel J. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021 02 25; 384(8):705-716.
-
Dwyer AR, Truong TH, Kerkvliet CP, Paul KV, Kabos P, Sartorius CA, Lange CA. Insulin receptor substrate-1 (IRS-1) mediates progesterone receptor-driven stemness and endocrine resistance in oestrogen receptor+ breast cancer. Br J Cancer. 2021 01; 124(1):217-227.
-
Crump LS, Wyatt GL, Rutherford TR, Richer JK, Porter WW, Lyons TR. Hormonal Regulation of Semaphorin 7a in ER+ Breast Cancer Drives Therapeutic Resistance. Cancer Res. 2021 01 01; 81(1):187-198.
-
Dhar D, Raina K, Kumar D, Wempe MF, Bagby SM, Pitts TM, Orlicky DJ, Agarwal C, Messersmith WA, Agarwal R. Bitter melon juice intake with gemcitabine intervention circumvents resistance to gemcitabine in pancreatic patient-derived xenograft tumors. Mol Carcinog. 2020 10; 59(10):1227-1240.
-
Klein IA, Boija A, Afeyan LK, Hawken SW, Fan M, Dall'Agnese A, Oksuz O, Henninger JE, Shrinivas K, Sabari BR, Sagi I, Clark VE, Platt JM, Kar M, McCall PM, Zamudio AV, Manteiga JC, Coffey EL, Li CH, Hannett NM, Guo YE, Decker TM, Lee TI, Zhang T, Weng JK, Taatjes DJ, Chakraborty A, Sharp PA, Chang YT, Hyman AA, Gray NS, Young RA. Partitioning of cancer therapeutics in nuclear condensates. Science. 2020 06 19; 368(6497):1386-1392.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|